Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase III factorial trial of cabazitaxel and pelvic radiotherapy in high-risk localized prostate cancer
2012-000566-38Phase 3Active
- Sponsor
- Unicancer
- Start
- Apr 2013
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cabazitaxel in prostate cancer (PCa) (4 arms), sponsored by Unicancer. Primary endpoint: Clinical Progression-Free Survival at 6 years. Started Apr 2013; status: active.
02
Drugs
cabazitaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2012-000566-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000566-38.